Navigation Links
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
Date:3/7/2013

operating margin18.7%

18.6%17.9%

20.6%Adjustments:Share-based compensation3,409

3,107

9.7%14,314

11,473

24.8%Amortization of acquired intangible assets408

484

(15.7%)1,983

1,549

28.0%Revaluation of contingent consideration(3,391)

-

NA(3,391)

-

NAImpairment charges for goodwill and intangible assets3,415

-

NA3,415

-

NANon-GAAP operating income27,398

23,803

15.1%105,740

96,832

9.2%Non-GAAP operating margin21.8%

21.9%21.2%

23.8%GAAP net income23,821

23,481

1.4%86,584

80,979

6.9%GAAP net margin19.0%

21.6%17.3%

19.9%Adjustments:Share-based compensation3,409

3,107

9.7%14,314

11,473

24.8%Amortization of acquired intangible assets408

484

(15.7%)1,983

1,549

28.0%Deferred tax impact related to acquired intangible assets(150)

(137)

9.5%(734)

(591)

24.2%Revaluation of contingent consideration(3,391)

-

NA(3,391)

-

NAImpairment charges for goodwill and intangible assets3,415

-

NA3,415

-

NANon-GAAP net income27,512

26,935

2.1%102,171

93,410

9.4%Non-GAAP net margin21.9%

24.8%20.4%

22.9%GAAP net income23,821

23,481

1.4%86,584

80,979

6.9%Add back:Depreciation and amortization11,468

9,361

22.5%41,672

33,997

22.6%Interest (income) expenses, net(1,487)

(1,819)

(18.3%)(6,010)

(5,266)

14.1%Income tax expenses (benefit)4,508

3,917

15.1%17,393

16,606

4.7%EBITDA38,310

34,940

9.6%139,639

126,316

10.5%Adjustments:Sh
'/>"/>

SOURCE Wuxi PharmaTech Co. Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
2. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
3. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
4. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
5. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
6. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
7. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
8. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
9. WuXi PharmaTech Announces Second-Quarter 2012 Results
10. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
11. WuXi PharmaTech Announces First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
(Date:11/26/2014)... 2014 / -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD ... chain in China based on ... appointment of Ms. Rebecca Yingnan Zhang as ... Ms.Zhang has over 20 years of experience in ... Prior to Ms. Zhang,s appointment as the Company,s Chief ...
(Date:11/24/2014)... SEATTLE , Nov. 24, 2014 ... granted Breakthrough Therapy Designation to the company,s JCAR015 ... for the treatment of relapsed or refractory B-cell ... collaboration partner, Memorial Sloan Kettering Cancer Center, where ... "The FDA,s action is important news ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
... Cardiac Science Corporation , a global leader in automated ... monitoring devices that connect to electronic medical record ... it has completed certification with Allscripts Professional ... connectivity solution for its resting ECG, stress, and Holter ...
... and Drug Commissioner Dr. Margaret Hamburg today conducted an unusual ... a forum hosted by the National Organization for Rare Disorders ... Hamburg could share with the patient advocates her vision for ... concerns. "I come today to ask for your ...
Cached Medicine Technology:Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 2Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 3Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 4Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 5NORD Hosts Forum for FDA Commissioner and Patient Leaders 2
(Date:11/26/2014)... Increasing incidence rate of adverse ... are expected to be prime pharmacovigilance market growth ... acute and chronic ailments has resulted in a ... Moreover, growing adverse drug reaction related hospitalization rates, ... the need of the hour in the pharmaceutical ...
(Date:11/26/2014)... For its December issue , Atlantic ... on Blue Cross and Blue Shield Plans* interviewed officials ... strategies the two Blues plans are implementing in order ... sleep apnea, ranging from brick-and-mortar retail stores to patient ... increased rates of a variety of serious disorders, including ...
(Date:11/26/2014)... November 26, 2014 Senior Planning Services, ... SeniorNet, a nonprofit organization providing the adult demographic ... to help seniors navigate the rough seas of applying ... educating seniors on the topic of Medicaid eligibility and ... complicated process of applying for this coverage. , ...
(Date:11/26/2014)... Medical suction and vacuum products have a ... score represents steady growth in the price of medical ... a result of swelling demand for healthcare services and ... considered nondiscretionary. IBISWorld market research analyst, Anna Son, says, ... of flexibility, given the low level of price volatility ...
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, Jennifer E. ... Award from The American Association of Nurse ... of nurse practitioners. The Distinguished Preceptorship Award recognizes ... a significant contribution toward increasing the awareness and ... Practitioners (AANP) is the largest full-service national professional ...
Breaking Medicine News(10 mins):Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2
... Homeless & Mentally IllNEW YORK, April 29 May ... on it, philanthropic-minded New Yorkers will raise money for ... ill and physically disabled. As federal and state ... in the current economy, supporters will raise funds amidst ...
... the first about his popular cookie-based diet, Dr. Sanford Siegal combines ... history of weight-loss diets through the Ages , ... ... Diet Book (Hyde Park Publishing Ltd., hardcover, 320 pages, ISBN 978-0-9822728-3-1) ...
... institute of LASIK is Featured in Cataract & refractive surgery ... practice. , ... Westlake, Ca (Vocus) April 29, 2009 ... LASIK, was featured in the highly respected trade journal, Cataract ...
... workforce development and productivity, announced today that Emergency Consultants, Inc. ... has switched to the LearnCenter platform to offer Continuing Medical ... ... (PRWEB) April 29, 2009 -- ...
... As cleanup from this year,s record floods continue in ... Association is providing the city some badly needed good news. ... the best cities for ozone pollution, short-term particle pollution and ... million Americans live in areas that failed all three tests. ...
... by nausea and sensitivity to light and sound, sufferers are ... forced to stop what they are doing until the pain ... productivity at work and the personal lives of those affected. ... more than three migraine attacks per month are looking ...
Cached Medicine News:Health News:Weston United Celebrates Mental Health Month on May 19th 2Health News:Dr. Siegal's Cookie Diet Book by Sanford Siegal, D.O., M.D., Available May 22nd 2Health News:Dr. Siegal's Cookie Diet Book by Sanford Siegal, D.O., M.D., Available May 22nd 3Health News:Dr. Siegal's Cookie Diet Book by Sanford Siegal, D.O., M.D., Available May 22nd 4Health News:Dr.Khanna Featured in Highly Respected Trade Journal 2Health News:Dr.Khanna Featured in Highly Respected Trade Journal 3Health News:Emergency Consultants Inc. switches to Learn.com to deliver Continuing Medical Education (CME) courses to physicians 2Health News:Emergency Consultants Inc. switches to Learn.com to deliver Continuing Medical Education (CME) courses to physicians 3Health News:Migraine prevention by targeting glutamate receptors? 2Health News:Migraine prevention by targeting glutamate receptors? 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: